[{"id":"0eefbaf9-a4ea-454b-868c-1b99280a8dd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01541709","created_at":"2021-01-18T06:30:56.005Z","updated_at":"2024-07-02T16:35:24.757Z","phase":"Phase 2","brief_title":"Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI","source_id_and_acronym":"NCT01541709","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 9 mutation","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 9 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-01"},{"id":"ea5d6031-d473-42c0-8a28-91a62279cacc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03609424","created_at":"2021-01-18T17:44:34.659Z","updated_at":"2025-02-25T15:43:08.795Z","phase":"Phase 1/2","brief_title":"PDR001 Plus Imatinib for Metastatic or Unresectable GIST","source_id_and_acronym":"NCT03609424","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1","pipe":" | ","alterations":" KIT mutation • KIT exon 9 mutation • KIT exon 13 mutation","tags":["KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 9 mutation • KIT exon 13 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Stivarga (regorafenib) • spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 11/11/2021","primary_completion_date":" 11/11/2021","study_txt":" Completion: 11/11/2021","study_completion_date":" 11/11/2021","last_update_posted":"2023-01-02"},{"id":"65aa546b-6373-4d3e-bd0b-ba34a643210e","acronym":"ZJGIST-01","url":"https://clinicaltrials.gov/study/NCT04933669","created_at":"2021-06-22T15:52:32.553Z","updated_at":"2024-07-02T16:36:23.163Z","phase":"Phase 2","brief_title":"Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT04933669 - ZJGIST-01","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2021-10-12"},{"id":"bd33213e-1e75-4d66-a7df-4eb6b35fb14c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01874665","created_at":"2021-01-17T17:54:42.275Z","updated_at":"2024-07-02T16:37:10.653Z","phase":"Phase 2","brief_title":"A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT01874665","lead_sponsor":"Ariad Pharmaceuticals","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 06/05/2013","start_date":" 06/05/2013","primary_txt":" Primary completion: 02/28/2015","primary_completion_date":" 02/28/2015","study_txt":" Completion: 07/31/2016","study_completion_date":" 07/31/2016","last_update_posted":"2018-05-18"}]